TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants in Modified Clinical Remission at Week 12 (Traditional Endoscopic Subscore <=1, Observed Cases)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants in Modified Clinical Remission at Week 12 (Traditional Mayo Endoscopic Subscore <=1, Treatment Failure Approach)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants in Modified Clinical Remission at Week 12 (Modified Mayo Endoscopy Subscore = 0 or 1, Observed Cases)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants in Modified Clinical Remission at Week 12 (Modified Mayo Endoscopy Subscore = 0 or 1, Treatment Failure Approach)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance rate of peritoneal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary 8-isoprostane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients Who Withdrew Due to Intolerance to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Scanned bladder volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Estimated Post Void Residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Drainage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: safety and efficacy of cholecystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of macular oedema relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: technical efficiency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence and incidence of current HCV infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sustained Viral Response 12 Weeks After Last Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes of neurocognitive biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of autonomic dysfunctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of REM-related EMG activity and motor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional connectivity of large-scale brain networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain measured by visual-analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects with reported Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects with Clinically significant changes in Electrocardiogram measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects with Clinically meaningful changes in Vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects with Clinically significant changes in laboratory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of the Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ocular Discomfort Score (ODS) on a Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anesthetized Schirmer Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain Intensity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Reported Opioid Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Reported Opioid Use Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of a febrile neutropenic episode
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in frequency and/or intensity of menopause symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects reaching blood pressure target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Magnitude of systolic blood pressure reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Magnitude of diastolic blood pressure reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of mammaglobin-A DNA vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in self-reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in student's skills score for bed bath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ultrasound Strain Measurements (Gray Scale Median Value) on Carotid Plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in In-vivo velocity measured by Transcranial Doppler (TCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Impairment Index - General Cognitive Morbidity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of treatment-emergent serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Remission Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of fractional carbon dioxide laser treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Melatonin Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DEXA-measured Adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proton Density Fat Fraction (PDFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Carotid Artery Intima Media Thickness (CIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Serum Cortisol Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Mullen Scales of Early Learning (MSEL)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline Vineland Adaptive Behavior Scales, Second Edition (VABS-II)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hospitalization with heart failure decompensation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Anaerobic exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Laboratory Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Signs and Symptoms of Progressive Multifocal Leukoencephalopathy (PML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Human Anti-human Antibodies (HAHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Event-Related Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of arterial disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Malaria infectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bacterial proliferation potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of periprosthetic joint infection
Endpoint domain: Adverse events/effects
Primary endpoint: Pain and Disability Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall Survival Rate (10-year)
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients needing intensive care unit admission
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients needing non-invasive ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients needing mechanical ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Opioid Negative Urine Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between DTI imaging measures and 3D morphological MRI measures for point of penetration of the pelvic splanchnic nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Agreement between DTI imaging measures and 3D morphological MRI measures for point of penetration of the pelvic hypogastric nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Agreement between DTI imaging measures and 3D morphological MRI measures for origin of the cavernous nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heart function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Viral Load-time Curve (VL-AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Unacceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: 3-Year Event Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in apnea/hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Number of Urinary Urge Incontinence Episodes Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall comparison with usual contact lenses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clarity and comfort of contact lenses
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maintenance of healthy, white eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and nature of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Montgomery-Ashberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: local Inbreast Breast Tumor Recurrence (IBTR) rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean Decitabine Area Under the Concentration Versus Time Curve (AUC0-t) on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Maximum %LINE Demethylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of contrast medium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesion incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Independence in daily life assessed by Barthel Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Independence in daily life assessed by Lawton-Brody Instrumental Activities of Daily Living (IADL) scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Determine DLTs and RP2Ds
Endpoint domain: Adverse events/effects
Primary endpoint: Determine safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of obstructive defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: elimination of plantar warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intra-Examiner Agreement in Angle Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-Examiner Agreement in Angle Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in experience of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Renal Elimination Rate Constant of Tobramycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Drinks Per Drinking Day (DDPW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in plasma biomarkers reflecting endothelial damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in platelet count reflecting platelet consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean change in biomarkers reflecting fibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Engraftment ratio of human AML cells to murine cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of sorafenib or quizartinib to inhibit AML proliferation in vivo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in cerebral blood flow based on BOLD contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of complications related to bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of complications related to infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in the Daily Average Number of Micturition Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Titers for Serum Hemagglutination Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Factor (SCF) for HI Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants who test negative for COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent change in global myocardial perfusion reserve (MPR) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak increase in modified preload-adjusted maximal power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in maximum severity of cyclic breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Longitudinal Change in Autism Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Picking up Prescription on Intended Date of Pickup
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: TV4 BGMS performance data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vasospasm at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vasospasm at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vasospasm at 4 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vasospasm at 6 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients with adequately-controlled hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to adequate control of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fear of Cancer Progression and Recurrence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Weight gain during pregnancy within IOM's recommendation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Predictive value of sentinel lymph node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Successful CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revocation Rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of HIV and other STIs
Endpoint domain: Mortality/survival
Primary endpoint: extracellular polysaccharides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHF hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resonance Frequency Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AUC of amprenavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of amprenavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of abacavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of abacavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poor outcome of the disease
Endpoint domain: Mortality/survival
Primary endpoint: advanced stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: increased vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Gap between baseline mean arterial pressure and lowest mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of regular gastric slow waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bacterial Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Functional gastrointestinal disease diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: fibrovascular membrane over iris surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incremental area under the blood plasma concentration curve of eicosapentaenoic acid (EPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental area under the blood plasma concentration curve of docosahexaenoic acid (DHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental area under the blood plasma concentration curve of Vitamin E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Respiratory Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-anesthesia awaking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease on Visual Analogue Scale (VAS) score for Fibromyalgia related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scales of the Fibromyalgia Impact Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in score on Beck Depression Inventory II at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline scores on trait form of the State Trait Anxiety Inventory at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in resting HRV High Frequency Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Transvaginal NOTES cholecystectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Transvaginal NOTES cholecystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of cystic fibrosis participants with NTM isolates in related clusters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes